The French National Health Insurance fund, known as the Caisse nationale de l’Assurance maladie (Cnam), has officially identified “deprescribing” as a central strategy in its 2027 “Charges and Products” report to optimize pharmaceutical expenditure and improve patient safety. This initiative seeks to empower pharmacists to actively participate in the review and potential discontinuation of unnecessary or redundant medications, particularly for elderly patients managing multiple chronic conditions.
As a physician, I view this shift as a significant evolution in primary care. The goal is not merely cost-containment, but the reduction of iatrogenic risks—harm resulting from medical treatment—associated with polypharmacy. By leveraging the proximity and expertise of community pharmacists, the health authorities aim to streamline complex treatment regimens that often accumulate over years of fragmented care.
The Expanded Role of Pharmacists in Medication Management
The proposal outlined by the Cnam centers on the formalization of medication reviews. While pharmacists have long provided counseling, this new framework would integrate them more deeply into the therapeutic decision-making process. According to the official Cnam annual report on charges and products, the strategy involves identifying patients who are at risk of adverse drug events due to the sheer volume of their daily intake.
Pharmacists will be encouraged to conduct structured interviews to assess the relevance of ongoing treatments. When a medication appears to offer diminishing returns or presents a high risk of interaction, the pharmacist is expected to facilitate a dialogue with the prescribing physician. This collaborative approach is designed to ensure that the patient remains at the center of the decision, with the physician retaining the final authority on clinical adjustments.
Why Deprescribing Matters for Public Health
Polypharmacy, defined generally as the concurrent use of five or more medications, is a growing public health challenge in aging populations. Data from the French National Authority for Health (HAS) has historically indicated that excessive medication usage significantly increases the risk of falls, cognitive impairment, and hospitalizations among seniors. By systematically reviewing these prescriptions, the Cnam intends to mitigate these risks while simultaneously addressing the sustainability of the national health budget.
The initiative also addresses the “prescribing cascade,” where new drugs are added to treat the side effects of existing medications, creating an unnecessary cycle of pharmacological intervention. Pharmacists are uniquely positioned to spot these patterns because they often see the cumulative list of prescriptions from multiple specialists, a view that a single physician may not always have.
Implementation Challenges and Next Steps
Translating this strategy into clinical practice requires robust coordination. Success depends on the digital interoperability of health records, allowing pharmacists, general practitioners, and specialists to share a single, accurate view of a patient’s medical history. The Cnam has emphasized that this process must be supported by appropriate remuneration for the time pharmacists invest in these clinical reviews, a detail that remains a subject of ongoing negotiations with professional unions.
The next major checkpoint for this policy will be the legislative and regulatory debate surrounding the Social Security Financing Bill (PLFSS), where the specific funding mechanisms and implementation timelines will be finalized. As the healthcare landscape continues to shift toward more integrated, multidisciplinary care, the role of the pharmacist as a frontline guardian of patient safety is set to become increasingly prominent.
Have you or a family member participated in a medication review with your local pharmacist? Share your experiences in the comments below, or join the conversation on our social media platforms. For the latest official updates on the 2027 health financing strategies, readers are encouraged to monitor the Service-Public.fr portal for legislative announcements.